Remy S Petersen, Lauré M Fijen, Christian Apfelbacher, Markus Magerl, Karsten Weller, Werner Aberer, Adil Adatia, Paul Audhya, Noémi-Anna Bara, Stephen Betschel, Isabelle Boccon-Gibod, Laurence Bouillet, Nicholas Brodszki, Paula J Busse, Thomas Buttgereit, Anette Bygum, Mauro Cancian, Timothy Craig, Dorottya Csuka, Henriette Farkas, Daria Fomina, Johana Gil-Serrano, Mark Gompels, Guillermo Guidos Fogelbach, Mar Guilarte, Michihiro Hide, Sorena Kiani-Alikhan, Tamar Kinaciyan, Annet Lenten, Ramon Lleonart, Hilary Longhurst, William R Lumry, Alejandro Malbran, Laura Malinauskiene, Juan J Matta Campos, Joan Mendivil, Sandra A Nieto-Martinez, Jonathan G Peter, Grzegorz Porebski, Avner Reshef, Marc Riedl, Anna Valerieva, Susan Waserman, Marcus Maurer, Danny M Cohn
BACKGROUND: Clinical trials investigating drugs for acute treatment of hereditary angioedema attacks have assessed many different outcomes. This heterogeneity limits comparability of trial results and may lead to selective outcome reporting bias and a high burden on trial participants. OBJECTIVE: To achieve consensus on a Core Outcome Set comprising key outcomes that should ideally be utilized in all clinical efficacy trials involving acute treatment of hereditary angioedema attacks...
April 10, 2024: Journal of Allergy and Clinical Immunology in Practice